Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, Thomas J. Kipps et al.|New England Journal of Medicine|2018Cited by 907
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Chan Y. Cheah et al.|The Lancet Oncology|2022Cited by 429
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, William G. Wierda, Barbara Eichhorst et al.|Journal of Clinical Oncology|2018Cited by 313
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1Pramod K. Mistry, Michel Peterschmitt, Elena Lukina et al.|JAMA|2015Cited by 156
Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trialPramod K. Mistry, Michel Peterschmitt, Elena Lukina et al.|American Journal of Hematology|2017Cited by 99